Amiodarone-associated optic neuropathy in the treatment of cardiovascular diseases
https://doi.org/10.21516/2072-0076-2020-13-2-83-87
Abstract
An increase in the growth of cardiovascular diseases has been observed in the last few years. Cardiac rhythm disturbances, especially atrial fibrillation, in absence of cardioversion and proper prophylaxis lead to thromboembolic complications. Drug therapy in rhythm disorders consists of the many antiarrhythmic drugs, prescribed for a long period of time. This fact can result to the ocular toxicy, which have insidious and slow progression. First and foremost, there is a risk of amiodarone-associated toxicity. Amiodarone affects as anterior segment structures (photosensitivity, corneal and conjunctiva deposits, anterior subcapsular cataract) as posterior segment structures (optic neuropathy). Fibers of the papillomacular bundle are the most vulnerable structures in optic nerve to the toxic effect of amiodarone due to the absence of myelination and salutatory conduction, their small size and high-energy requirements. The difficulties in diagnosis of amiodarone-associated optic neuropathy are related to slow progression (patients don’t notice symptoms until the late stages) and clinical similarity to ischemic optic neuropathy.
About the Authors
E. E. Ioyleva
S. Fyodorov Eye Microsurgery Federal State Institution
Russian Federation
Russian Federation
Elena E. Ioyleva – Dr. of Med. Sci., Professor, scientific secretary
59a, Beskudnikovsky blvd, Moscow, 127486
N. A. Gavrilova
A.I. Evdokimov Moscow State University of Medicine and Dentistry
Russian Federation
Russian Federation
Natalia A. Gavrilova – Dr. of Med. Sci., Professor, head of chair of eye diseases
20, p. 1, Delegatskaya St., Moscow, 127473
A. V. Zinov’eva
A.I. Evdokimov Moscow State University of Medicine and Dentistry
Russian Federation
Russian Federation
Aleksandra V. Zinov’eva – resident, chair of eye diseases
20, p. 1, Delegatskaya St., Moscow, 127473
M. V. Kats
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
Mikhail V. Kats – student, department of general medicine
8, p. 2, Trubetskaya st., Moscow, 119991
References
1. Oganov R.G., Koncevaja A.V., Kalinina A.M. Economic damage from cardiovascular diseases in the Russian Federation. Kardiovaskuljarnaja terapija i profilaktika. 2011; 4: 4–9 (in Russian).
2. Shal'nova S.A., Konradi A.O., Karpov Ju.A., et al. Analysis of mortality from cardiovascular diseases in 12 regions of the Russian Federation participating in the study “Epidemiology of cardiovascular diseases in various regions of Russia”. Rossijskij kardiologicheskij zhurnal. 2012; 5 (97): 6–1 (in Russian).
3. Filatov A.G., Tarashvili E.G. Epidemiology and social significance of atrial fibrillation. Annaly Aritmologii. 2012; 2: 5–13 (in Russian).
4. Ushkalova E.A., Zyrjanov S.K., Dumchenko E.V. Approaches to antithrombotic therapy in elderly patients with atrial fibrillation. Racional'naja farmakoterapija v kardiologii. 2017; 13 (2): 275–83 (in Russian). http://dx.doi.org/10.20996/181964462017-13-2-275-283
5. Epifanov V.G., Dolgih V.T. A comparative study of the effectiveness of emergency care in attacks of atrial fibrillation in patients with arterial hypertension and ischemic heart disease in the prehospital phase. Rossijskij kardiologicheskij zhurnal. 2010; 3 (83): 74–7 (in Russian).
6. Zotova I.V., Isaeva M.Ju., Alekhin M.N. Thromboembolic risk assessment for atrial fibrillation: current state of the problem. Aterotromboz. 2013;1: 21–31 (in Russian).
7. Sulimov V.A. Diagnosis and treatment of atrial fibrillation. Recommendations VNOK and VNOA. Racional'naja farmakoterapija v kardiologii. 2011; 4: 1–82 (in Russian).
8. Sharma P., Sharma R. Toxic optic neuropathy. Indian J. Ophthalmol. 2011; 59 (2): 137–41. doi: https://doi.org/10.4103/0301-4738.77035
9. Kerrison J.B. Optic neuropathies caused by toxins and adverse drug reactions. Ophthalmol. Clin. North Am. 2004; 17 (3): 481–8. https://doi.org/10.1016/j.ohc.2004.05.005
10. Phillips P.H., Toxic and deficiency optic neuropathies. In: Miller N.R., Newman N.J., Biousse V., Kerrison J.B., eds. Walsh and Hoyt’s Clinical Neuro-ophthalmology. 2005; 6: 455–6.
11. Behbehani R. Clinical approach to optic neuropathies. Clin. Ophthalmol. 2007; 1 (3 Sep.): 233–46. PMID: 19668477.
12. Carelli V., Ross-Cisneros F.N., Sadun A.A. Optic nerve degeneration and mitochondrial dysfunction: genetic and acquired optic neuropathies. Neurochem. Int. 2002; 40: 573–84. https://doi.org/10.1016/s0197-0186(01)00129-2
13. Wang M.Y., Sadun A.A. Drug-related mitochondrial optic neuropathies. J. Neuroophthalmol. 2013; 33: 172–8. https://doi.org/10.1097/wno.0b013e3182901969
14. Sharma M., Volpe N.J., Dreyer E.B. Methanol-induced optic nerve cupping. Arch. Ophthalmol. 1999; 117 (2): 286. https://doi.org/10.1001/archopht.117.2.286
15. Barboni P., Carbonelli M., Savini G., et al. OPA1 mutations associated with dominant optic atrophy influence optic nerve head size. Ophthalmology. 2010; 117: 1547–53. https://doi.org/10.1016/j.ophtha.2009.12.042
16. Barboni P., Savini G., Valentino M.L., et al. Retinal nerve fiber layer evaluation by optical coherence tomography in Leber’s hereditary optic neuropathy. Ophthalmology. 2005; 112: 120–6. https://doi.org/10.1016/j.ophtha.2004.06.034
17. Macaluso D.C., Shults W.T., Fraunfelder F.T. Features of amiodaroneinduced optic neuropathy. Am. J. Ophthalmol. 1999; 127 (5): 610–2. https://doi.org/10.1016/s0002-9394(99)00016-1
18. Immordino L., Connolly S., Crijns H., et al. Effects of dronedarone started rapidly after amiodarone discontinuation. Clin. Cardiol. 2013; 36 (2): 88–95. https://doi.org/10.1002/clc.22090
19. Vassallo P., Trohman R.G. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA. 2007; 298: 1312–22. https://doi.org/10.1001/jama.298.11.1312
20. Raizman M.B., Hamrah P., Holland E.J., et al. Drug-induced corneal epithelial changes. Survey of Ophthalmology. 2017; 62: 286–301. https://doi.org/10.1016/j.survophthal.2016.11.008
21. Flach A.J., Dolan B.J. Amiodarone-induced lens opacities: an 8-year follow-up study. Arch Ophthalmol. 1990; 108: 1668–9.
22. Kazaryan A.A., Obvintseva L.V., Lebenkova O.A., Barsegyan A.S. Amiodarone-induced optic neuropathy: clinical cases. Russian ophthalmological journal. 2015; 8 (4): 43–53 (in Russian).
23. Cheng H.C., Yeh H.J., Huang N., et al. Amiodarone-associated optic neuropathy: a nationwide study. Ophthalmology. 2015; 122 (12 Dec.): 2553–9.
24. Macaluso D.C., Shults W.T., Fraunfelder F.T. Features of amiodaroneinduced optic neuropathy. Am. J. Ophthalmol. 1999; 18 (5): 610–2.
25. Nicolas J., Hendriksen P.J., de Haan L.H., et al. In vitro detection of cardiotoxins or neurotoxins affecting ion channels or pumps using beating cardiomyocytes as alternative for animal testing. Toxicol. in Vitro. 2015; 29: 281–8. https://doi.org/10.1016/j.tiv.2014.11.010
26. Turovaya A.Y. Effects of verapamil and amiodarone on sympathoadrenal system and balance of excitatory and inhibitory aminoacids in rat medulla oblongata. Bull. Exp. Biol. Med. 2005; 139: 665–7. https://doi.org/10.1007/s10517-005-0372-5
27. Silver P.J., Connell M.J., Dillon K.M., et al. Inhibition of calmodulin and protein kinase C by amiodarone and other class III antiarrhythmic agents. Cardiovasc. Drugs Ther. 1989; 3: 675–82. https://doi.org/10.1007/bf01857619
28. Passman R.S., Bennett C.L., Purpura J.M., et al. Amiodaroneassociated optic neuropathy: a critical review. Am. J. Med. 2012; 125 (5): 447–53. https://doi.org/10.1016/j.amjmed.2011.09.020
29. Johnson L.N., Krohel G.B., Thomas E.R. The clinical spectrum of amiodarone-associated optic neuropathy. J. Natl. Med. Assoc. 2004; 96: 1477–91. PMC2568612
30. Nagra P.K., Foroozan R., Savino P.J., Castillo I., Sergott R.C. Amiodarone induced optic neuropathy. Br. J. Ophthalmol. 2003; 87: 420–2. doi:10.1136/bjo.87.4.420
31. Mansoor A.M., Puklin J.E., O’Grady R. Optic nerve ultrastructure following amiodarone therapy. J. Clin. Neuro-ophthalmol. 1988; 8: 231–7. PMID:2977138
32. Latini R., Tognoni G., Kates R.E. Clinical pharmacokinetics of amiodarone. Clin. Pharmacokinet. 1984; 9: 136–56. https://doi.org/10.2165/00003088-198409020-00002
33. Yamreudeewong W., DeBisschop M., Martin L.G., Lower D.L. Potentially significant drug interactions of class III antiarrhythmic drugs. Drug Saf. 2003; 26 (6): 421–38. https://doi.org/10.2165/00002018200326060-00004
34. Venkatesh N., Singh B.N., Al-Sarraf L., Kannan R. Digoxindesethylamiodarone interaction in the rat: comparison with the effects of amiodarone. J. Cardiovasc. Pharmacol. 1986; 8 (2): 309–13. doi:10.1097/00005344-198603000-00013
35. Rennie I.G. Clinically important ocular reactions to systemic drug therapy. Drug Saf. 1993; 9 (3): 196–211. https://doi.org/10.2165/00002018-199309030-00005
36. Purvin V., Kawasaki A., Borruat F.X. Optic neuropathy in patients using amiodarone. Arch. Ophthalmol. 2006; 124 (5): 696–701. doi:10.1001/archopht.124.5.696
37. Martínez-López-Portillo A., Martínez-Gamero B., Mohamed-Noriega J., Cavazos-Adame H., Mohamed-Hamsho J. Behavior of disc oedema during and after amiodarone optic neuropathy: Case Report. Journal of Clinical and Diagnostic Research. 2014; 8 (4): VD04VD05. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4064863/
38. Di Biase L., Mohanty P., Mohanty S., et al. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial. Circulation. 2016; 134 (10): e189-e190. https://doi.org/10.1161/circulationaha.116.024003
39. Sapp J.L., Wells G.A., Parkash R., et al. Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs. N. Engl. J .Med. 2016; 375: 111–21. https://doi.org/10.1056/nejmoa1513614
Review
For citations:
Ioyleva E.E., Gavrilova N.A., Zinov’eva A.V., Kats M.V. Amiodarone-associated optic neuropathy in the treatment of cardiovascular diseases. Russian Ophthalmological Journal. 2020;13(2):83-87. (In Russ.) https://doi.org/10.21516/2072-0076-2020-13-2-83-87
Views:
2397
Email this article 